GlobalData
GlobalData

Pharma

China’s blockchain-backed recovery from COVID-19 could pave way to create efficient disease surveillance system, says GlobalData

Despite the COVID-19 outbreak, China managed to launch its national blockchain-based service network (BSN) in April 2020, as scheduled earlier, in an attempt to promote the mass adoption of blockchain and explore the opportunities that the digital economy can bring. China has been an early adopter of technologies to fight COVID-19 and will be closely observed […]
Read more

Success of new research projects crucial in containing community spread of COVID-19 in India, says Globaldata

The Department of Science and Technology – Science and Engineering Board (DST-SERB) has recently initiated several special research projects. These efforts could help contain community spread of the novel coronavirus (COVID-19) in India, says GlobalData, a leading data and analytics company. According to GlobalData COVID-19 dashboard, as of 05 May 2020, India has 46,437 confirmed cases […]
Read more

Calibrated financial support to bolster India’s preparedness in fight against COVID-19, says GlobalData

Following the news that India has approved nearly US$2bn* towards ‘India COVID-19 Emergency Response and Health System Preparedness Package’; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “The move comes as no surprise as the COVID-19 situation has seen some unprecedented decisions taken swiftly by the Indian government. […]
Read more

COVID-19 pandemic may restrict patients’ access to medical marijuana

The COVID-19 pandemic is set to impact the pharmaceutical industry in a profound way, according to GlobalData, a leading data and analytics company. From postponed and suspended clinical trials to stockpiling of painkillers causing disruption to supply chains, the medical marijuana industry is also expected to be affected by the ongoing crisis.    GlobalData’s report: ‘Medical […]
Read more

High-dose chloroquine should not be used further for COVID-19 patients due to the QTc prolongation, says GlobalData

Recent results have shown that high-dose chloroquine has potential safety concerns resulting in QTc prolongation, a heart rhythm disorder that serves as a surrogate indicator for increased risk of drug-associated torsades de pointes (TdP). GlobalData believes that the preliminary data from this Phase II study indicates that high-dose chloroquine should not be used further for […]
Read more

Phase 2 Kevzara trial provides important insight into the management of COVID-19

Regeneron and Sanofi recently announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab), an antibody targeting the interleukin-6 (IL-6) receptor, in hospitalized patients with severe or critical respiratory illness caused by COVID-19. Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData, comments: “Targeting the correct patient population […]
Read more

India needs to step up healthcare spending to combat outbreaks such as COVID-19 in future, says GlobalData

With an unexpected spike in COVID-19 cases, India has extended the countrywide lockdown till 17 May 2020. The move reflects India’s dependency on lockdown to contain the pandemic amid poor healthcare spending and infrastructure, says GlobalData, a leading data and analytics company. According to GlobalData COVID-19 dashboard, as of 04 May 2020, although India has  42,505 […]
Read more

Cereno Scientific’s novel CS-1 holds potential as it enters crowded PAH marke

Cereno Scientific’s preclinical candidate CS-1 (valproic acid) was recently granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) for the US market for pulmonary arterial hypertension (PAH) —a rare, fatal cardiopulmonary disease with no curative treatment. Provided its successful clinical development, CS-1 has the potential to carve out a space on the market, due to its novel mechanism of action, says GlobalData, a leading data and analytics company. […]
Read more

Digital transformation in healthcare services is accelerated by COVID-19

The fast-paced adoption of digital technologies is emerging as a key element of remodeling healthcare delivery and scaling up systems. While the risk-averse culture, legacy systems, regulation and compliance challenges are hindering the uptake of emerging technologies in healthcare services, COVID-19 may be the trigger that will accelerate digitalization in the sector, says GlobalData, a […]
Read more

UK start-up companies’ AI to accelerate search for COVID-19 treatment

Start-up companies in the UK are turning to artificial intelligence (AI) for analysis of existing drugs and new molecules. The use of AI in this way has the potential to rapidly accelerate the research and development (R&D) timeline, allowing faster COVID-19 drug development. The COVID-19 pandemic may be a tipping point in companies adopting AI-facilitated […]
Read more

Real-world evidence can help countries deal with the COVID-19 outbreak

Organizations are relying on real-world evidence (RWE) to help tcontain the spread of COVID-19. Real-world data can provide valuable insights to help organizations better understand, monitor and prepare for the any challenges that the outbreak presents, says GlobalData, a leading data and analytics company. In a GlobalData poll of 935 respondents, conducted from April 6–20, more […]
Read more

IBD industry could be at risk during COVID-19

As the COVID-19 global pandemic grows with the UK, active inflammatory bowel disease (IBD) patients could be at a higher risk, as patients using prominent therapies such as Remicade and Humira could cause an increased risk of bacterial and viral infections, says GlobalData, a leading data and analytics company. In order to protect active IBD patients, […]
Read more

Pre-emptive planning and manufacturing support initiatives could help avoid potential shortages in cancer drugs amid COVID-19 pandemic

Concerns have arisen that treatments for cancer patients could be affected by shortages in cancer drug supply and distribution as valuable medical resources are being diverted for the management of the COVID-19 pandemic. The outbreak has overtaxed healthcare systems worldwide as countries are struggling to contain the spread of the infection, says GlobalData, a leading […]
Read more
1 93 94 95 96 97 108